Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 2595

1.

Nomogram predicting treatment-related bowel dysfunction for men with localized prostate cancer treated by radical prostatectomy (RP), external-beam radiotherapy (EBRT), and brachytherapy (PI).

Michalski JM, Sanda MG, Litwin MS, Ferrer M, Hamstra DA, Regan MM, Saigal C, Kwan L, Gao T, Klein EA, Kattan MW, Stephenson AJ.

J Clin Oncol. 2012 Dec;30(34_suppl):55. doi: 10.1200/jco.2012.30.34_suppl.55.

PMID:
28146976
2.

Nomogram predicting treatment-related sexual dysfunction for men with localized prostate cancer treated by radical prostatectomy (RP), external-beam radiotherapy (EBRT), and brachytherapy (PI).

Sanda MG, Litwin MS, Ferrer M, Regan MM, Saigal C, Kwan L, Gao T, Klein EA, Kattan MW, Stephenson AJ.

J Clin Oncol. 2012 Dec;30(34_suppl):51. doi: 10.1200/jco.2012.30.34_suppl.51.

PMID:
28146962
3.

Nomogram predicting treatment-related urinary incontinence for men with localized prostate cancer treated by radical prostatectomy (RP), external-beam radiotherapy (EBRT), or brachytherapy (PI).

Sanda MG, Litwin MS, Ferrer M, Regan MM, Saigal C, Kwan L, Gao T, Klein EA, Kattan MW, Stephenson AJ.

J Clin Oncol. 2012 Dec;30(34_suppl):49. doi: 10.1200/jco.2012.30.34_suppl.49.

PMID:
28146931
4.

Nipple-sparing subcutaneous mastectomy (NSSM) as dual-plane prosthetic reconstruction using the modified Wise pattern mastectomy, fasciocutaneous flap, and titan-polypropylen-mesh-interponation in women with macromastia.

Klein E, Ettl J, Niemeyer M, Bronger H, Paepke D, Kiechle M.

J Clin Oncol. 2012 Sep 20;30(27_suppl):156. doi: 10.1200/jco.2012.30.27_suppl.156.

PMID:
28146762
5.

Subpectoral implants in oncoplastic-reconstructive breast surgery: Habit or necessity?

Dittmer S, Rezai A, Klein E, Kiechle M.

J Clin Oncol. 2012 Sep 20;30(27_suppl):161. doi: 10.1200/jco.2012.30.27_suppl.161.

PMID:
28146740
6.

Vitamin E and the risk of prostate cancer: Updated results of the Selenium and Vitamin E Cancer Prevention Trial (SELECT).

Klein EA, Thompson I, Tangen CM, Lucia MS, Goodman P, Minasian LM, Ford LG, Parnes HL, Gaziano JM, Karp DD, Lieber MM, Walther PJ, Parsons JK, Chin J, Darke AK, Lippman SM, Goodman GE, Meyskens FL, Baker LH.

J Clin Oncol. 2012 Feb 10;30(5_suppl):7. doi: 10.1200/jco.2012.30.5_suppl.7.

PMID:
28143337
7.

Long-term toxicity and associated cost of initial treatment and subsequent toxicity-related intervention for patients treated with prostatectomy, external beam radiotherapy, or brachytherapy: A SEER/Medicare database study.

Ciezki JP, Reddy CA, Angermeier K, Ulchaker J, Stephans KL, Tendulkar RD, Altman A, Chehade N, Klein EA.

J Clin Oncol. 2012 Feb 10;30(5_suppl):4. doi: 10.1200/jco.2012.30.5_suppl.4.

PMID:
28143333
8.

Effect of neoadjuvant docetaxel treatment for locally advanced prostate cancer on miRNA expression: A pilot study.

Falzarano SM, Zhou M, Carver P, Klein EA, Dreicer R, Magi-Galluzzi C.

J Clin Oncol. 2012 Feb 10;30(5_suppl):139. doi: 10.1200/jco.2012.30.5_suppl.139.

PMID:
28143212
9.

Identifying patients with node-positive prostate cancer who may benefit from adjuvant pelvic radiation following prostatectomy.

Shukla ME, Reddy CA, Stephans KL, Stephenson AJ, Klein EA, Garcia JA, Dreicer R, Tendulkar RD.

J Clin Oncol. 2012 Feb 10;30(5_suppl):195. doi: 10.1200/jco.2012.30.5_suppl.195.

PMID:
28143198
10.

Prostate cancer-specific mortality and competing causes of mortality among elderly men after local therapy for prostate cancer.

Mir MC, Klink JC, Isariyawongse B, Kibel AS, Klein EA, Stephenson AJ.

J Clin Oncol. 2012 Feb 10;30(5_suppl):103. doi: 10.1200/jco.2012.30.5_suppl.103.

PMID:
28143063
11.

Impact of different definitions of high-risk prostate cancer on survival after radical prostatectomy.

Nepple KG, Sandhu GS, Kallogjeri D, Strope SA, Grubb RL, Klein EA, Stephenson AJ, Kibel AS.

J Clin Oncol. 2012 Feb 10;30(5_suppl):113. doi: 10.1200/jco.2012.30.5_suppl.113.

PMID:
28143029
12.

Comparing long-term toxicity between external beam radiotherapy modalities: A SEER/Medicare database study.

Reddy CA, Ciezki JP, Abdel-Wahab M, Angermeier K, Ulchaker J, Stephans KL, Tendulkar RD, Altman A, Chehade N, Klein EA.

J Clin Oncol. 2012 Feb 10;30(5_suppl):118. doi: 10.1200/jco.2012.30.5_suppl.118.

PMID:
28143021
13.

Identification of prostate cancer-expressed microRNAs associated with clinical recurrence (cR) and prostate cancer-specific survival (PCSS) following radical prostatectomy (RP).

Klein EA, Kiefer M, Crager M, Magi-Galluzzi C, Falzarano SM, Pelham RJ, Millward C, Cherbavaz DB, Baker J, Shak S, Lee M.

J Clin Oncol. 2012 Feb 10;30(5_suppl):21. doi: 10.1200/jco.2012.30.5_suppl.21.

PMID:
28142917
14.

Salvage brachytherapy for prostate bed recurrence following radical prostatectomy.

Ciezki JP, Stephans KL, Reddy CA, Klein EA.

J Clin Oncol. 2013 Feb 20;31(6_suppl):218. doi: 10.1200/jco.2013.31.6_suppl.218.

PMID:
28137040
15.

Patient-reported sexual and urinary function after open and robotic radical prostatectomy.

Li J, Klein EA, Kaouk J, Jones JS, Stephenson AJ.

J Clin Oncol. 2013 Feb 20;31(6_suppl):120. doi: 10.1200/jco.2013.31.6_suppl.120.

PMID:
28136818
16.

Variations in treatment modality use for the definitive management of prostate cancer in the United States.

Reddy CA, Ulchaker J, Angermeier K, Stephans KL, Tendulkar RD, Stephenson AJ, Chehade N, Altman A, Klein EA.

J Clin Oncol. 2013 Feb 20;31(6_suppl):174. doi: 10.1200/jco.2013.31.6_suppl.174.

PMID:
28136787
17.

Photoselective vaporization of the prostate compared to transurethral resection of the prostate in patients who develop prostatic obstruction following brachytherapy.

Reddy CA, Ciezki JP, Angermeier K, Ulchaker J, Klein EA, Wood H.

J Clin Oncol. 2013 Feb 20;31(6_suppl):187. doi: 10.1200/jco.2013.31.6_suppl.187.

PMID:
28136767
18.

Abstracts of the 26th World Congress on Ultrasound in Obstetrics and Gynecology, Rome, Italy, 24-28 September 2016.

Roux-Dessarps L, Klein E, Blanc T, Bessières B, Heidet L, Stirnemann J, Chalouhi GE, Ville Y, Aigrain Y, Salomon LJ.

Ultrasound Obstet Gynecol. 2016 Sep;48 Suppl 1:250. doi: 10.1002/uog.16744. No abstract available.

PMID:
27645454
19.

Impact of 5α-reductase inhibitors on disease reclassification among men on active surveillance for localized prostate cancer with favorable features.

Dai C, Ganesan V, Zabell J, Nyame YA, Almassi N, Greene DJ, Hettel D, Reichard C, Haywood SC, Arora H, Zampini A, Crane A, Li J, Elshafei A, Magi-Galluzzi C, Stein RJ, Fareed K, Gong M, Jones JS, Klein EA, Stephenson AJ.

J Urol. 2017 Aug 5. pii: S0022-5347(17)77259-X. doi: 10.1016/j.juro.2017.08.006. [Epub ahead of print]

PMID:
28789947

Supplemental Content

Loading ...
Support Center